Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Enanta Pharmaceuticals Inc ENTA

Healthcare Biotechnology
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered... see more

Recent & Breaking News (NDAQ:ENTA)

Enanta Pharmaceuticals Announces U.S. Regulatory Approval of TECHNIVIE(TM) (ombitasvir, paritaprevir and ritonavir) tablets

Business Wire July 24, 2015

Enanta Pharmaceuticals Announces the Appointment of Nathalie Adda, M.D. as Chief Medical Officer

Business Wire June 30, 2015

AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis

PR Newswire June 24, 2015

Enanta Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

Business Wire June 16, 2015

Enanta Announces SVR12 results of 95% from AbbVie's GIFT-1 Study in Non-cirrhotic, Japanese Patients with Genotype 1b Hepatitis C Virus1

Business Wire May 26, 2015

AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis

PR Newswire May 26, 2015

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2015

Business Wire May 7, 2015

Enanta Pharmaceuticals to Present at the Deutsche Bank 40th Annual Healthcare Conference

Business Wire April 27, 2015

Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Second Quarter and Six-Months Ended March 31, 2015

Business Wire April 27, 2015

Enanta Pharmaceuticals Announces Preliminary Data from AbbVie's Phase 3b RUBY-I Study in Chronic Hepatitis C Patients with Renal Impairment Presented at The International Liver Congress(TM) 2015

Business Wire April 25, 2015

AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress(TM) 2015

PR Newswire April 25, 2015

Enanta Announces U.S. FDA Grants Priority Review for AbbVie's Investigational, All-Oral, Interferon-Free Treatment Regimen for Genotype 4 Chronic Hepatitis C Infection

Business Wire April 23, 2015

Enanta Pharmaceuticals Announces AbbVie's Investigational Treatment Regimen for Genotype 1 Chronic Hepatitis C Granted Priority Review in Japan

Business Wire April 15, 2015

AbbVie's Investigational Chronic Hepatitis C Treatment Granted Priority Review in Japan

PR Newswire April 15, 2015

Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitors Paritaprevir and ABT-493 at The International Liver Congress(TM) 2015

Business Wire April 8, 2015

AbbVie to Present New Data from Hepatitis C Clinical Development Program at The International Liver Congress(TM) 2015

PR Newswire April 8, 2015

Enanta Pharmaceuticals to Present at Barclays Global Healthcare Conference

Business Wire March 3, 2015

Enanta Announces JAMA Publication of Results from AbbVie's Study of VIEKIRA PAK(TM) (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I)

Business Wire February 23, 2015

Results from AbbVie's Study of VIEKIRA PAK(TM) (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) Published Online in JAMA; Sub-analyses to be Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI)

PR Newswire February 23, 2015

Enanta Announces AbbVie Submits New Drug Application to the Japanese Ministry of Health, Labour and Welfare for its Investigational, All-Oral, Treatment for Chronic Hepatitis C

Business Wire February 12, 2015